Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

  • Stanislas Pol, Reem H Ghalib, Vinod K Rustgi, Claudia Martorell, Greg T Everson, Harvey A Tatum, Christophe Hézode, Joseph K Lim, Jean-Pierre Bronowicki, Gary A Abrams, Norbert Bräu, David W Morris, Paul J Thuluvath, Robert W Reindollar, Philip D Yin, Ulysses Diva, Robert Hindes, Fiona McPhee, Dennis Hernandez, Megan Wind-Rotolo, Eric A Hughes, Steven Schnittman
  • The Lancet Infectious Diseases, September 2012, Elsevier
  • DOI: 10.1016/s1473-3099(12)70138-x

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/s1473-3099(12)70138-x

The following have contributed to this page: Eric Hughes and Dr Joseph K Lim